|Mr. Paul F. Truex MBA||Exec. Chairman||626.32k||4.36k||48|
|Mr. John Craig Thompson||Chief Exec. Officer, Pres and Director||533.55k||N/A||50|
|Ms. May Liu||Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer||373.44k||N/A||41|
|Dr. William R. Shanahan Jr., M.D., J.D.||Chief Medical Officer and Sr. VP||195.95k||N/A||68|
|Ms. Klara A. Dickinson-Eason||Advisor||417.89k||N/A||49|
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, CA, US.
Anthera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.